August 2012 Br J Cardiol 2012;19:104–06 doi:10.5837/bjc.2012.022
Jonathan Morrell
Reducing the residual cardiovascular risk that remains after statin use is a frontline challenge for preventive cardiology. After attention to other modifiable risk factors, further reduction of low-density lipoprotein cholesterol (LDL-C) levels and increasing high-density lipoprotein cholesterol (HDL-C) levels are under particular scrutiny.1,2 The cardioprotective epidemiology of HDL-C is strong and well known, and so it often comes as a shock to health professionals that there is no direct proof that raising HDL-C improves cardiovascular outcomes. Despite this, raising HDL-C remains an attractive potential approach for tackling residual ris
July 2006 Br J Cardiol 2006;13:273-7
Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen, on behalf of the NAUTILUS Study Group
No content available
July 2006 Br J Cardiol 2006;13:278-82
Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen, on behalf of the NAUTILUS Study Group
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
